Abstract
A critical appraisal and clinical application of Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742-748. doi: 10.1007/s10620-006-9312-0
DOI
10.22237/crp/1469036125
Recommended Citation
Kane W. It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide. Clin. Res. Pract. 2016 July;2(2):eP1114. doi: 10.22237/crp/1469036125
Included in
Gastroenterology Commons, Hepatology Commons, Medical Education Commons, Nephrology Commons, Translational Medical Research Commons
